Ignite Creation Date:
2024-05-06 @ 11:01 AM
Last Modification Date:
2024-10-26 @ 12:38 PM
Study NCT ID:
NCT03409614
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-25
First Post:
2018-01-10
Brief Title:
Combinations of Cemiplimab Anti-PD-1 Antibody and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Sponsor:
Regeneron Pharmaceuticals
Organization:
Regeneron Pharmaceuticals
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-03-06
Start Date Type:
ACTUAL
Primary Completion Date:
2025-02-03
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-02-03
Completion Date Type:
ESTIMATED
First Submit Date:
2018-01-10
First Submit QC Date:
January 23 2018
Study First Post Date:
2018-01-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-24
Last Update Post Date:
2024-04-25
Last Update Post Date Type:
ACTUAL